Monitoring the microcirculation of patients with advanced lungcancer treated with bevacizumab and chemotherapy using optical spectroscopy.

Lungcancer is the second most common cancer in men and women, and is the
leading cause of cancer related death. In industrialized countries it kills
more patients than breast, colorectal and prostate cancer combined. Eighty-five
percent of patients with lungcancer have non-small-cel-lungcancer (NSCLC), and
60% of these patients present with an incurable stage IIIB or IV disease.
Prognosis of advanced lungcancer (both small cell and non-small cell) is bad.
Unfortunately, only palliative rather than curative treatment options are
present for these advanced cancers. Platinum-based chemotherapy is currently
the standard treatment in these patients and median survival time is typically
6-9 month after this standard therapy. [1]

2.1 Primary objectives

Primary objective is scientific research to study the additional effect of
bevacizumab on hypoxia related parameters.


2.2 Secondary objectives

a) To compare the efficacy of bevacizumab with pre-treatment obtained values of
blood hypoxia related parameters.
b) To study the effect of standard treatment of chemotherapy without
bevacizumab on hypoxia related parameters.

suspicion of lung carcinoma
*
bronchoscopy with DPS after informed consent METC
*
NSCLC stage IV disease or extended SCLC
*
informed consent present trial randomisation
* *
standard treatment with bevacizumab standard treatment without

bevacizumab

* *
repeated bronchoscopy with DPS
*
treatment according to institutional policy

Standard risk by bronchscopy: damaging of the vocalcord, haemoptoe,
pneumothorax, hypoxemia, arrhythmias.